US regulators are scheduled to rule on two GSK medicines a month apart, on 26 October and 27 November, giving investors a pair of binary-looking events in an otherwise guidance-driven quarter.
Drug companies live by two calendars. One is the financial calendar of results, dividends and guidance. The other is the regulatory calendar, where a single decision can shape a product's prospects for a decade. For GSK (LSE:GSK), one of the largest companies in the FTSE 100, the regulatory calendar has two important entries before the end of November.
According to GSK's third-quarter pre-announcement aide memoire, published on 8 October 2026, the US Food and Drug Administration is due to make a decision on bepirovirsen by Monday 26 October 2026 and on neladalkib by Friday 27 November 2026.
How FDA decision dates work
When a drugmaker files an application for a new medicine in the US, the FDA sets a target date by which it aims to complete its review. These goal dates give companies and investors a timetable, but they do not ensure a particular outcome.
Broadly, there are three ways a decision date can play out:
- Approval. The FDA approves the medicine, sometimes with specific conditions about how it can be used, labelled or monitored.
- A rejection or request for more information. The agency can decline to approve the application in its current form and set out what it would need to see, which may include further data or changes to manufacturing.
- A delay. The review period can be extended, for example if the company submits significant new information late in the process.
The label that comes with an approval matters almost as much as the approval itself. It determines which patients a medicine can be prescribed for, and therefore how large its potential market may be. For this reason, investors often look beyond the headline decision to the details of what has been approved.
Why two decisions in two months matter
For a company of GSK's size, a single approval rarely transforms near-term earnings. New medicines usually take time to build sales as doctors become familiar with them, insurers agree on coverage and supply is ramped up. The effect of an approval tends to show up first in analysts' forecasts for future years rather than in the current year's numbers.
Even so, the two dates are significant for sentiment. Pharmaceutical valuations depend heavily on what investors think a company's pipeline will deliver once older products face competition. Each approval adds a potential source of growth to that picture, while a setback can lead to a reassessment of future revenue.
Having two decisions so close together means GSK's newsflow will be unusually concentrated in the coming weeks. The bepirovirsen decision is due two days before the Autumn Budget on 28 October, while the neladalkib decision lands near the end of a quarter in which, according to the same aide memoire, GSK's profit growth is weighted.
Setting the decisions against guidance
The regulatory dates arrive alongside a full set of financial targets. GSK's 2026 guidance, at constant exchange rates, calls for turnover growth of 3–5%, in the upper half of that range; core operating profit growth of 7–9%, also in the upper half; and core earnings per share growth of 7–9%, in the lower half. The company expects to pay a 70p dividend for the year.
GSK has also said it expects net interest costs of about £800m, including the effect of its acquisition of Nuvalent, which completed on 15 July 2026, and that foreign exchange will reduce third-quarter turnover by about 1%.
For illustration, the spread of the turnover range shows how much is already priced into guidance. On a hypothetical base of £100 of turnover, growth of 3% would give £103 and growth of 5% would give £105. Guiding to the upper half means GSK expects somewhere between £104 and £105 on that basis. A new product approved late in the year would contribute little to that range, which is why the decisions matter more for later years.
There was also encouraging news from elsewhere in the group. On 6 October, ViiV Healthcare's Cabenuva met its primary endpoint in a study, adding to the flow of clinical updates across the business.
The FTSE 100 closed up 1.1% at 10,552.05 on Friday 9 October and gained 0.9% over the week. Bond markets have been a recurring influence: the 10-year gilt yield touched 5.53% intraday on Thursday 8 October, its highest since July 2007, before easing on Friday. Healthcare shares are often valued for their relatively steady earnings, so rising yields can make them look less attractive compared with bonds. Sterling, which ended Friday at $1.3233, also matters for a group that reports in pounds but earns heavily in other currencies.
Sector news has also been active in the US. AstraZeneca (LSE:AZN) announced on 5 October that it is investing more than $1bn in Massachusetts as part of a wider $50bn US investment plan, including a new R&D centre at Kendall Square. That underlines how central the US market is to large UK-listed drugmakers, and why decisions by the FDA carry so much weight.
Key dates to watch
- Wed 21 October: UK CPI for September.
- Mon 26 October: FDA decision date for GSK's bepirovirsen.
- Wed 28 October: Autumn Budget from Chancellor John Healey.
- Thu 5 November: Bank of England MPC decision and Monetary Policy Report.
- Fri 27 November: FDA decision date for GSK's neladalkib.
The bottom line
GSK faces two US regulatory decisions in quick succession: bepirovirsen on 26 October and neladalkib on 27 November. Approval would add potential new sources of growth, while a delay or rejection could prompt a reassessment of pipeline expectations. Neither decision is likely to change the 2026 numbers much, as the company's guidance already sets out the expected path for the year. Investors may watch both the outcomes and the details of any approved labels, which tend to shape the longer-term picture more than the decision dates themselves.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...